ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment

Wang, Yuehua; Wang, Zhenjie; Jia, Fei; Xu, Qing; Shu, Zhilin; Deng, Junlin; Li, Aimin*; Yu, Meng*; Yu, Zhiqiang*国家纳米科学中心; 南方医科大学; 中国科学院
Bioactive Materials2022-11DOI: 10.1016/j.bioactmat.2022.01.003
27被引22阅读
引用收藏
分享

摘要

Clinical sorafenib treatment could activate C-X-C receptor type 4 (CXCR4)/stromal source factor-1 alpha (SDF-1 alpha) axis to aggravate intra-tumoral hypoxia of hepatocellular carcinoma (HCC), which further leads to progression, invasion, metastasis, and immunosuppression of tumors and in return causes resistance to sorafenib therapy. Therefore, a multi-functional oxygen delivery nanoplatform was rationally constructed based on an oxygen-saturated perfluorohexane (PFH)-cored liposome, with the CXCR4 antagonist LFC131 peptides modifying on the surface to simultaneously deliver sorafenib and the CSF1/CSF1R inhibitor PLX3397 (named PFH@LSLP) for sorafenib-resistant HCC treatment. The PFH@LSLP was developed to overcome sorafenib resistance by synergistic effects of the following 3 roles: 1) the O-2-saturated PFH core could alleviate the tumor hypoxia by O-2 supply; 2) the LFC131 peptide recognized the hypoxia-related overexpressed CXCR4 and then blocked SDF-1 alpha/CXCR4 axis to re-sensitize the HCC cells to sorafenib; 3) PLX3397 activated the immune responses via inhibiting the CSF1/CSF1R pathway in TAMs, further enhanced CD8(+) T cell infiltration to reverse immunosuppression in tumors. Antitumor performance on H22 tumor-bearing mice and HCC patient-derived tumor xenograft (PDX) model showed that PFH@LSLP could overcome sorafenib resistance by synergistic effect of hypoxia attenuation, resistance-related gene regulation, and immune-microenvironment modification.

学科与关键词

关键词
Hepatocellular carcinomaSorafenib resistanceHypoxia reliefImmunotherapyTumor targeting regulation
相关
加载中…
  • Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy
    Huang, Linzhuo; Xu, Rui; Li, Weirong; Lv, Li; Lin, Chunhao; Yang, Xianzhu; Yao, Yandan; Saw, Phei Er*; Xu, Xiaoding*Acta Biomaterialia, 2023, 162: 98-109.被引 3
  • Near-Infrared Light Laser-Triggered Release of Doxorubicin and Sorafenib from Temperature-Sensitive Liposomes for Synergistic Therapy of Hepatocellular Carcinoma
    Peng, Yuan*; Su, Zhenwei; Wang, Xin; Wu, Teng; Xiao, Hong; Shuai, Xintao; Lan, Yue*Journal of Biomedical Nanotechnology, 2020, 16(9): 1381-1393.被引 6
  • Sorafenib-Based Drug Delivery Systems: Applications and Perspectives
    Wang, Lingyun*; Chen, Meihuan; Ran, Xueguang; Tang, Hao; Cao, DerongPolymers, 2023, 15(12): 2638.
查看全部 →

发表信息

论文状态
公开发表
期刊
Bioactive Materials
发表日期
2022-11
卷期
第 17 卷
页码
147-161
DOI
10.1016/j.bioactmat.2022.01.003
期刊等级
1区
成果收录
SCIE

作者

  • W

    Wang, Yuehua (第一作者)

    southern med univ · new

  • W

    Wang, Zhenjie

查看全部 9 位作者收起作者
  • J

    Jia, Fei

    cas · natl ctr nanosci & technol china

  • X

    Xu, Qing

    new · southern med univ

  • S

    Shu, Zhilin

    new · southern med univ

  • D

    Deng, Junlin

    new · southern med univ

  • L

    Li, Aimin (通讯)

    southern med univ

  • Y

    Yu, Meng (通讯)

    new · southern med univ

  • Y

    Yu, Zhiqiang (通讯)

    new · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417